RT Journal Article
SR Electronic
T1 Susceptibility to monkeypox virus infection: seroprevalence of orthopoxvirus in 4 population samples; France, Bolivia, Laos and Mali
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.15.22277661
DO 10.1101/2022.07.15.22277661
A1 Luciani, Léa
A1 Lapidus, Nathanaël
A1 Amroun, Abdennour
A1 Falchi, Alessandra
A1 Souksakhone, Chanthala
A1 Mayxay, Mayfong
A1 Dubot-Pérès, Audrey
A1 Saba Villarroel, Paola Mariela
A1 Diarra, Issa
A1 Koita, Ousmane
A1 Gallian, Pierre
A1 de Lamballerie, Xavier
YR 2022
UL http://medrxiv.org/content/early/2022/07/17/2022.07.15.22277661.abstract
AB Europe is experiencing an epidemic of monkeypox virus against a background of limited knowledge of population immunity to orthopoxviruses. We tested antibodies neutralizing vaccinia virus in blood samples from Bolivia (n=601), Laos (n=657), Mali (n=255) and France (n=4876). We also tested neutralization of cowpox virus in 4448 French samples, which confirmed extensive cross-immunity between both viruses. Using a cut-off titer of 20, seroprevalence is <1% in Bolivia, <5% in Laos (mainly related to vaccination in the elderly), 17.25% in Mali (related to both smallpox vaccination and the likely natural circulation of orthopoxviruses). In France, neutralizing antibodies are found (but at low prevalence) in age groups supposed to be vaccinated, suggesting both decrease in antibody titer in vaccinated individuals and decline in smallpox vaccine compliance before the end of compulsory vaccination. We conclude that the populations tested in Europe, Africa, Asia and South-America are massively susceptible to orthopoxvirus (e.g. monkeypox) infections.Article summary line Seroprevalence of orthopoxvirus tested on 4 continents is very low, even for people born before the eradication of smallpox, making populations vulnerable to the emergence of zoonotic orthopoxviruses such as monkeypox virus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the European Unions Horizon 2020 Research and Innovation Programme under grant agreement 653316 (European Virus Archive goes global project: http://www.european-virus-archive.com/).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Comite de Protection des Personnes Sud Mediterranee I Ethics committee of the Medical College of Santa Cruz Lao National Health Research Ethics Committee Oxford Tropical Research Ethics Committee Ethics committee of the National Institute for Public Health Research in MaliI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors